Director at $CTSH Sells 3,000 Shares in Insider Sale
The recent sale of 3,000 shares of $CTSH stock by Michael Patsalos-Fox, a company director, for an estimated $255,462 on 12-22-2025 has garnered attention. This transaction, disclosed via an SEC filing, accounted for roughly 6.7% of Patsalos-Fox’s share holdings in this particular class of stock, leaving them with 41,729 shares of $CTSH stock.
In the last 6 months, $CTSH insiders have actively traded the company’s stock on the open market 18 times, with all 18 transactions being sales. Michael Patsalos-Fox stands out with 5 sales totaling 23,965 shares, resulting in an estimated $1,937,698. Other key insiders, such as SURYA GUMMADI, RAVI KUMAR SINGISETTI, JOHN SUNSHIN KIM, and ALINA KERDMAN, have also engaged in significant sales of $CTSH stock.
Institutional investors have displayed contrasting behaviors regarding $CTSH stock in the most recent quarter. While 452 entities have added shares to their portfolios, 566 have decreased their positions. Noteworthy movements include UBS AM, which added 3,949,442 shares to their portfolio, and WELLINGTON MANAGEMENT GROUP LLP, which removed 3,278,541 shares.
As for the financial performance of $CTSH, the company reported revenues of $5.4B in Q3 2025, indicating a 7.36% rise compared to the same period in the previous year. This growth trajectory is reflective of the company’s operational performance.
In the realm of congressional stock trading, members of Congress have engaged in $CTSH stock transactions twice in the past 6 months, with an equal split between purchases and sales. Representative LISA C. MCCLAIN has been involved in both trades, making one purchase and one sale each, amounting to $15,000.
Wall Street analysts have been closely monitoring $CTSH, providing valuable insights through their reports. Notably, 5 firms have issued buy ratings for the stock in recent months, indicating a positive sentiment towards $CTSH. Moreover, multiple analysts have set price targets for $CTSH, with a median target of $83.5.
It is important to note that the information presented in this article is not financial advice and readers are encouraged to refer to Quiver Quantitative’s disclaimers for complete information and understanding. It is advisable to stay informed and make well-calculated decisions based on all available data and expert analyses.